MG-262

• CAT Number: M034274
• CAS Number: 179324-22-2
• Molecular Formula: C25H42BN3O6
• Molecular Weight: 491.43
• Purity: ≥95%
• Synonyms: [(1R)-3-methyl-1-[[(2S)-4-methyl-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]butyl]boronic acid
• InChI: InChI=1S/C25H42BN3O6/c1-16(2)12-20(24(31)29-22(26(33)34)14-18(5)6)27-23(30)21(13-17(3)4)28-25(32)35-15-19-10-8-7-9-11-19/h7-11,16-18,20-22,33-34H,12-15H2,1-6H3,(H,27,30)(H,28,32)(H,29,31)/t20-,21-,22-/m0/s1
• InChIKey: MWKOOGAFELWOCD-FKBYEOEOSA-N
• SMILES: B([C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1)(O)O

MG-262（Cat No.:M034274）is a potent, selective inhibitor of the proteasome, a complex responsible for degrading unneeded or damaged proteins within cells. By inhibiting proteasome activity, MG-262 disrupts protein homeostasis, leading to the accumulation of dysfunctional proteins, which induces cell cycle arrest and apoptosis, particularly in cancer cells. It has shown promise in preclinical studies as a potential therapeutic agent for various cancers, including multiple myeloma and solid tumors. Despite its potential, further clinical trials are needed to assess MG-262’s safety, efficacy, and effectiveness when used alone or in combination with other therapies.